
BCTXF
Healthcare · Biotechnology · $4.6M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Jan 31, 2021 | Time not confirmed | — | -0.41 | — |
| Oct 31, 2020 | Time not confirmed | — | -0.50 | — |
| Jul 31, 2020 | Time not confirmed | — | -0.71 | — |
| Apr 30, 2020 | Time not confirmed | — | -0.70 | — |
| Jan 31, 2020 | Time not confirmed | — | -1.97 | — |
| Oct 31, 2019 | Time not confirmed | — | -1.83 | — |
| Jul 31, 2019 | Time not confirmed | — | -1.96 | — |
| Apr 30, 2019 | Time not confirmed | — | -1.94 | — |
| Jan 31, 2019 | Time not confirmed | — | -2.22 | — |
| Oct 31, 2018 | Time not confirmed | — | -1.49 | — |
| Jul 31, 2018 | Time not confirmed | — | -3.12 | — |
| Apr 30, 2018 | Time not confirmed | — | -3.08 | — |
| Jan 31, 2018 | Time not confirmed | — | -2.11 | — |
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing…